Pharmacy Board warns against sale, import of unregistered products
Health & Science
By
Betty Njeru
| Jan 18, 2025
Government registered drugs found at a pharmacy in Kayole estate, Nairobi. [File, Standard]
The Pharmacy and Poisons Board (PPB) has issued a stern warning to health stakeholders against trading, importing, or handling unregistered pharmaceutical products in Kenya.
In a statement on Saturday, January 18, the PPB specifically cautioned against products referencing the Indian Pharmacopeia (IP).
“All stakeholders are hereby directed to cease and desist from trading, importing, or handling any unregistered products and ensure that all pharmaceutical products in their possession are duly registered and approved by the Pharmacy and Poisons Board,” the statement read.
The Board warned that noncompliance with this directive would result in the revocation of licenses and the seizure of products.
READ MORE
Ruto vows fight back against Trump tariffs on Kenyan goods
State vs private sector: Who should drive affordable housing agenda?
Why construction all risks insurance is key for projects
Trouble at top maritime school escalates
Nairobi June forum to accelerate development of new cities
Why tenants can't purchase their dwelling units
IMO banks on strict rules to curb ocean plastic pollution
KCB cuts rates in boon for borrowers
Africa is awake and rising economically- Ruto
Kisumu lakefront booms as hidden tourism gems transform region
The Indian Pharmacopeia is a set of standards for drugs and medicines manufactured, sold, and consumed in India.
However, the PPB clarified that these standards are not recognised under Kenya’s drug registration requirements, rendering products citing the IP non-compliant.
The Board further said it is actively monitoring the market and will take action against anyone found violating the regulatory framework.